WHO Updates Guidelines to Reject Two COVID-19 Antibody Therapies
The World Health Organization (WHO) has updated its guidelines to not recommend GSK and Vir Biotechnology’s sotrovimab and Regeneron and Roche’s casirivimab-imdevimab for use in patients with COVID-19.
WHO’s Guideline Development Group considered in vitro neutralization data demonstrating that sotrovimab and casirivimab-imdevimab evaluated in clinical trials have meaningfully reduced neutralization activity of the currently circulating variants of SARS-CoV-2 and their subvariants.
The panel concluded that the absence of in vitro neutralization activity strongly suggests absence of clinical effectiveness of these monoclonal antibodies.
However, the drugs’ effects against new variants and subvariants cannot be predicted, according to the guideline.